Time to clearance of high-risk human papillomavirus infection. At each visit [clinicaltrials_resource:226966a4dd7cf384a4870ae9daa17aae]
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Time to clearance of high-risk human papillomavirus infection. At each visit [clinicaltrials_resource:226966a4dd7cf384a4870ae9daa17aae]
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Bio2RDF identifier
226966a4dd7cf384a4870ae9daa17aae
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:226966a4dd7cf384a4870ae9daa17aae
measure [clinicaltrials_vocabulary:measure]
Time to clearance of high-risk human papillomavirus infection.
time frame [clinicaltrials_vocabulary:time-frame]
At each visit
description
851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
identifier
clinicaltrials_resource:226966a4dd7cf384a4870ae9daa17aae
title
Time to clearance of high-risk human papillomavirus infection. At each visit
@en
type
label
Time to clearance of high-risk ...... 966a4dd7cf384a4870ae9daa17aae]
@en